SARS-Hunter gives the possibility to hospitals to isolate the antibodies from plasma to be given as therapy and increases the chances of success of treatment, while reducing the side effects of plasma therapy given today.
This funding will enable RetiSpec to accelerate the commercialization of its groundbreaking technology aimed at early detection of Alzheimer's disease.
